KAFFEE: Innovative technology for metagenomic correction of human health
Achieving technological sovereignty for BRICS countries in the direction of metagenomic correction of human diseases Establishment of a Unified BRICS Donor Gut Microbiota Bank Ensuring BRICS leadership in the application of Fecal Microbiota Transplantation for a wide range of indications based on evidence-based medicine Exporting the metagenomic KAFFEE technology to countries beyond BRICS
Biotechnology And National Health
Technologies for human health
3 years
Russian Federation, Eurasian economic union, China
Regional segmentation analysis: The regions analyzed for the market include Europe, South America, Asia Pacific, North America, the Middle East, and Africa. North America emerged as the largest global fecal transplant therapy market, with a 46.37% market revenue share in 2023. North America dominates the fecal transplant therapy market due to the strong clinical pipeline of fecal microbiota transplants. Further, the rise in the incidence and prevalence of chronic diseases increased research & development expenditure, increasing awareness, and high regulatory approvals are expected to drive market growth in this region. Moreover, the high treatment rates, growing prescriptions for novel drugs, and better reimbursement policies are also helping to propel the market growth in this region over the forecast period. Additionally, the increasing prevalence of Inflammatory Bowel Diseases and developed healthcare facilities are expected to drive market growth in this region. Asia Pacific is expected to grow the fastest during the forecast period due to the large patient base. Moreover, the increased government initiatives toward developing fecal microbiota-based therapeutics and expanding the prescription of biosimilars are expected to drive market growth over the forecast period in this region.
N.A.
RU0002745125DEVICE AND THE METHOD FOR PREPARATION IN ANAEROBIC CONDITIONS OF DONOR FECAL MICROBIOTA FOR TRANSPLANTATION WO/2022/015192 CN220564596 EA202091623 IL285149
